Celgene (NASDAQ: CELG ) is one of biotechnology's brightest shining stars. The company markets a slate of therapies, including its mega blockbuster multiple myeloma drug Revlimid, its fast-growing cancer drug Abraxane, and its newly launched autoimmune drug, Otezla.
Despite Celgene's growing product lineup, shares are trading lower following the company's second quarter earnings report. As a result, investors are right to wonder if Celgene's winning streak is coming to an end.
In the following slideshow, you'll learn which of Celgene's drugs grew fastest and gain insight into whether shares are worth buying.
Leaked: This coming blockbuster will make Celgene jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.